

Special Issue

Boron Neutron Capture Therapy: Challenges, Past, Present and Future

Message from the Guest Editors

This Special Issue of *Cancers* will focus on critical issues that must be addressed to make boron neutron capture therapy (BNCT) a more effective therapeutic modality and bring it into the mainstream of radiation oncology.

These include the following:

- The selection of new boron delivery agents with superior tumor localizing properties compared to that of boronophenylalanine (BPA);
- The development of methods to determine tumor boron concentrations in cancer and normal tissues clinically in real time;
- The development of more precise and streamlined methods to determine tumor and normal tissue radiation doses in real time;
- The development of more versatile accelerator neutron sources that would be used both for patient treatment and for pre-clinical evaluation of new boron delivery agents;
- The identification of the most appropriate types of cancers that would be the best candidates to treat by means of BNCT.

In summary, what would be required to convince a broad audience of radiation oncologists that BNCT is a useful therapeutic modality would be incontrovertible evidence of its superiority over other therapeutic modalities.

Guest Editors

Prof. Dr. Rolf F. Barth

Department of Pathology, The Ohio State University, Columbus, OH 43210, USA

Prof. Dr. Nilendu Gupta

Division of Medical Physics, Department of Radiation Oncology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA

Deadline for manuscript submissions

closed (1 July 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/158553

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)